The tirzepatide mechanism of action activates two gut hormones at once. The first one (GLP-1) had been the star of obesity pharmacology for two decades. The second one (GIP) had been dismissed as a sidekick. Tirzepatide's clinical success made the field reconsider that dismissal.
Tirzepatide is a single 39-amino-acid peptide engineered to engage two receptors simultaneously: the GIP receptor and the GLP-1 receptor. Both receptors respond to gut-derived hormones (called incretins) released postprandially from intestinal endocrine cells. Each receptor contributes to glycemic control and body-weight reduction through partially different mechanisms. In the head-to-head SURPASS-2 trial, tirzepatide produced 11.2 kg of weight loss versus 5.7 kg for semaglutide — roughly twice the effect attributable to dual-receptor targeting.
For most of the GLP-1 era (roughly 2005 to 2020), GIP was the "forgotten incretin." Both hormones were discovered around the same time. Both originate from gut endocrine cells. GLP-1 received the bulk of drug-development attention because it produced clear glucose-lowering and weight-loss signals in clinical studies. GIP was largely dismissed, partly because research subjects with type 2 diabetes appeared to develop "GIP resistance" in hyperglycemic states.
Tirzepatide changed that. Eli Lilly's LY3298176 program was designed specifically to test whether reactivating GIP alongside GLP-1 would add meaningful benefit. The SURPASS and SURMOUNT trials answered that question definitively. This article walks through what each receptor does, how the molecule was engineered, and why dual targeting outperforms single GLP-1 alone.
The GLP-1 arm: the familiar half
GLP-1 (glucagon-like peptide-1) is a well-characterized incretin released from L-cells in the lower small intestine and colon postprandially. When it binds the GLP-1 receptor, studies have documented four principal downstream effects.
- Glucose-dependent insulin release. Pancreatic β-cells increase insulin secretion in proportion to circulating glucose. When glucose is low, the trigger does not fire — which is why GLP-1 receptor agonists have not been associated with hypoglycemia in studies of non-insulin-dependent subjects.
- Glucagon suppression. At postprandial levels, GLP-1 attenuates pancreatic α-cell glucagon secretion, reducing hepatic glucose output.
- Slowed gastric emptying. Preclinical and clinical studies have reported reduced gastric motility, prolonging nutrient transit and extending postprandial satiety signals.
- Central satiety signaling. GLP-1 receptors in the hindbrain and hypothalamus mediate appetite-suppression effects observed in animal models and human clinical trials.
Selective GLP-1 agonists (liraglutide, semaglutide) have produced roughly 6–15% weight reduction in clinical trials depending on dose — a ceiling the field had been working against prior to dual-agonist development.
Tirzepatide
The same compound cited across the SURMOUNT and SURPASS trials in this article. Lab-verified identity and purity.
The GIP arm: the underestimated half
GIP (glucose-dependent insulinotropic polypeptide, originally called gastric inhibitory polypeptide) is the other incretin. It is released from K-cells in the upper small intestine postprandially. Its receptor (GIPR) is expressed in pancreatic β-cells, adipose tissue, bone, and select brain regions.
A key mechanistic point established in the literature: GIP's receptor distribution only partially overlaps GLP-1's. The pancreatic distribution is shared. The adipose-tissue and brain distributions are largely distinct. Preclinical studies have attributed additive — rather than redundant — effects to simultaneous activation of both receptors, essentially engaging two partly-different downstream machines.
Documented effects of GIPR activation in published research:
- Augmented postprandial insulin secretion. GIPR and GLP-1R both drive glucose-dependent insulin release from pancreatic β-cells. Studies have reported that co-activation produces greater insulin output than either receptor alone at equivalent glycemic levels.
- Adipose lipid handling. GIP receptors in adipose tissue have been shown to modulate postprandial lipid storage and release. Clinical trial data have associated dual agonism with improved insulin sensitivity in adipose tissue beyond what weight reduction alone would predict.
- Additional central satiety signaling. GIPR activation has been reported to engage hypothalamic appetite circuits not fully reached by GLP-1R — including neuropeptide Y and POMC pathways — in preclinical models.
- Possible attenuation of GLP-1-driven nausea. Preclinical work has suggested GIPR co-agonism may reduce GLP-1-mediated nausea via central pathways. This remains under active investigation.
The clinical validation of GIPR co-agonism came from the SURPASS-2 trial. Tirzepatide outperformed semaglutide 1 mg on both glycemic control and weight reduction in study participants with type 2 diabetes — a head-to-head that effectively settled the "forgotten incretin" debate in the field.
How Eli Lilly engineered LY3298176
The compound now sold as Mounjaro and Zepbound was called LY3298176 in early development. Eli Lilly had been working on incretin co-agonist candidates for over a decade. The hypothesis was specific: hit both GIPR and GLP-1R, see if the combination beats either alone.
Three design choices distinguished LY3298176 from earlier dual-agonist attempts.
- The potency balance leans toward GIP. Tirzepatide binds GIPR roughly 5-fold tighter than GLP-1R — a deliberate design choice to emphasize the GIP arm's contribution to weight reduction beyond glucose control.
- Extended half-life via fatty-acid tail. Like semaglutide, tirzepatide carries a long C20 fatty-acid chain that reversibly binds albumin in plasma, extending the circulatory half-life to approximately one week and enabling once-weekly subcutaneous dosing in clinical use.
- 39-amino-acid linear peptide scaffold. The backbone builds on a GLP-1 / glucagon family template, with sequence modifications engineered to maintain dual-receptor binding and resist endogenous proteolytic degradation.
Phase II and III trials between 2018 and 2022 progressively built up the clinical profile. FDA approved tirzepatide as Mounjaro (for type 2 diabetes) in May 2022, and as Zepbound (for obesity) in November 2023.
The success of tirzepatide validates the dual-incretin hypothesis: simultaneous engagement of GIP and GLP-1 receptors produces consistently larger weight-loss magnitudes than GLP-1 alone, with a tolerability profile that remains broadly similar to the established GLP-1 class.
— Melson et al., International Journal of Obesity, 2024 (paraphrased summary)
Why does hitting two receptors beat one?
The SURPASS-2 head-to-head trial provides the most direct comparative evidence published to date. Frías and colleagues compared tirzepatide (5, 10, and 15 mg) directly against semaglutide 1 mg in 1,879 study participants with type 2 diabetes. Every tirzepatide dose outperformed semaglutide on both glycemic control and weight reduction. The 15 mg arm produced approximately 0.4 percentage points more HbA1c reduction and nearly twice the weight loss (11.2 kg vs 5.7 kg).
Three mechanisms have been proposed to explain the dual-agonist advantage.
Augmented pancreatic insulin secretion. Both receptors drive glucose-dependent insulin secretion through overlapping but non-identical intracellular pathways. Studies have reported that combined receptor activation produces greater insulin output than either receptor alone at matched glucose levels — accounting for much of the observed differential HbA1c reduction.
Broader central satiety signaling. GLP-1R and GIPR engage partly distinct hypothalamic circuits. GLP-1R activity is concentrated in hindbrain and POMC neuron pathways, while GIPR adds NPY-related circuits and additional hypothalamic targets. Co-activation of both receptor populations has been associated with larger appetite-suppression signals than single-receptor maximal stimulation in preclinical models.
Adipose lipid handling. GIPR expression in adipocytes modulates postprandial lipid storage and release via mechanisms that GLP-1R does not fully engage. Clinical trial data have shown that study participants receiving tirzepatide exhibited improvements in lipid profiles and insulin sensitivity exceeding what body-weight reduction alone would predict — a finding consistent with the distinct adipose GIPR component.
The key insight from SURPASS-2: dual-agonist superiority is not simply a dose-escalation effect. The trial results are consistent with distinct pharmacology — two partially non-overlapping receptor systems doing complementary work — rather than incremental pressure on a single pathway. That mechanistic distinction is what positioned tirzepatide as a category-defining compound rather than a marginal semaglutide improvement.
What about the GI side effects?
When tirzepatide first entered trials, one open question was whether adding GIPR agonism would worsen the GI tolerability profile seen with GLP-1 agonists. SURMOUNT and SURPASS data addressed this directly. At the highest doses studied, nausea was reported in roughly 33% of trial participants, diarrhea in 22%, and vomiting in 12%. Those rates are broadly similar to high-dose semaglutide — suggesting GIPR co-agonism did not materially worsen GI tolerability.
Some preclinical data has suggested GIPR co-agonism may actually attenuate GLP-1-driven nausea through central pathways, though this hypothesis remains under investigation. In the SURMOUNT and SURPASS clinical programs, GI adverse events were generally managed through gradual dose escalation protocols, consistent with the approach used for the established GLP-1 agonist class.
Where this falls short. Tirzepatide's dataset is large and well-characterized for T2D and obesity indications, but a head-to-head against high-dose semaglutide 2.4 mg in obesity has not been completed. The SURMOUNT vs SURPASS comparisons are cross-trial inferences, not direct head-to-head data. The cardiovascular outcomes data (SURMOUNT-MMO) is still pending. Long-term safety beyond 2 years of use is still being characterized. The compound's efficacy evidence is strong, but decades of longitudinal safety data — available for older agents like metformin — do not yet exist for tirzepatide.
What's next: the triple-agonist generation
Tirzepatide's success set the template for retatrutide. The logic was simple: if hitting two receptors beats hitting one, would hitting three beat hitting two?
Retatrutide adds a third receptor target: glucagon. That arm is not redundant with GIP or GLP-1. Glucagon receptor activation has been reported to boost basal energy expenditure and mobilize hepatic lipids — effects that tirzepatide's dual-agonist mechanism does not engage. The 2023 retatrutide Phase II data showed 24.2% mean weight loss at the highest dose, consistent with the hypothesis that each additional non-overlapping receptor target unlocks incremental weight-reduction magnitude.
Tirzepatide remains the current best-in-class FDA-approved compound. If retatrutide's Phase III data holds up, tirzepatide's role shifts. It goes from category leader to category foundation: the drug that proved multi-receptor targeting works before the triple-agonist generation took over.
Tirzepatide
39-aa dual GIP/GLP-1 agonist with C20 fatty-diacid acyl chain. The same reference compound used across the cited SURMOUNT and SURPASS trials. COA available with each lot.
What to know now
- Two receptors: GLP-1R (satiety, glucose-dependent insulin, slowed gastric emptying) and GIPR (more insulin, fat-tissue handling, brain satiety circuits).
- Mechanism complementarity: partly overlapping but partly different receptor distributions produce additive, not redundant, effects.
- SURPASS-2 head-to-head: tirzepatide beat semaglutide 1 mg at every dose on HbA1c and weight loss. That's the empirical validation of dual-agonism.
- Engineering choices: GIPR-leaning potency, C20 fatty-acid tail for once-weekly dosing, 39-amino-acid linear peptide.
- GI tolerability: nausea ~33%, diarrhea ~22%, vomiting ~12% at top doses in SURMOUNT/SURPASS trials. Rates broadly similar to high-dose semaglutide; GIPR co-agonism did not materially worsen the profile.
- Template for retatrutide: tirzepatide's success set up the triple-agonist generation that adds glucagon receptor activation on top.
What we're watching
Three things over the next 18 months. First, head-to-head trials of tirzepatide vs semaglutide 2.4 mg in obesity (not just T2D). The cross-trial comparison strongly suggests tirzepatide is better, but a direct trial would settle it for prescribing guidelines. Second, the SURMOUNT-MMO cardiovascular outcomes readout. The question: does tirzepatide deliver SELECT-equivalent heart benefit? Third, oral incretin formulations like orforglipron at Phase III. An oral GLP-1 or oral dual-agonist would change the prescribing math entirely.
References
- Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
- Aronne, L. J., Sattar, N., Horn, D. B., et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA, 331(1), 38–48. https://doi.org/10.1001/jama.2023.24945
- Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2024). What is the pipeline for future medications for obesity? International Journal of Obesity, 49(3), 433–451. https://doi.org/10.1038/s41366-024-01473-y